New antibiotic for UTI hits market
The U.S. Food and Drug Administration has approved a new drug to treat complicated urinary tract infections (cUTI). The antibacterial drug, created by Rempex Pharmaceuticals, can also treat pyelonephritis, a kidney infection caused by specific bacteria.
“The FDA is committed to making new safe and effective antibacterial drugs available,” said Edward Cox, MD, director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research, in a press release. “This approval provides an additional treatment for patients with cUTI, a type of serious bacterial infection.”
Vabomere is a drug containing meropenem, an antibacterial, and vaborbactam, which inhibits certain types of resistance mechanisms used by bacteria. It should only be used to treat infections proven or strongly suspected to be caused by susceptible bacteria.
The most common adverse drug reactions were headache, infusion site reactions and diarrhea. Vabomere is associated with serious risks, including allergic reactions and seizures, and should not be taken by people with a history of anaphylaxis.
Nicole was Senior Editor at I Advance Senior Care and Long Term Living Magazine 2015-2017. She has a Journalism degree from Kent State University and is finalizing a master’s degree in Information Architecture and Management. She has extensive studies in the digital user experience and in branding online media. She has worked as an editor and writer for various B2B publications, including Business Finance.
Topics: Clinical , Infection control